Vertex Pharmaceuticals Inc
Most Recent
Consumer.How Did Tesla Become Renaissance Technologies’ Gem?
In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.
Consumer.Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
Earnings Report.Amarin’s Q2 Earnings and Robust 2019 Outlook
Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.
Earnings Report.Vertex Pharmaceuticals Raises Guidance, Shares Follow
Yesterday, Vertex Pharmaceuticals reported its second-quarter results after the market closed. Today, it was up 1.73% in the premarket session.
Company & Industry Overviews.Analysts Have Raised Their Target Price for VRTX in March
Wall Street analysts expect a potential upside of 14.17% for Vertex Pharmaceuticals (VRTX) based on the stock’s closing price on March 21.
Company & Industry Overviews.Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
Company & Industry Overviews.A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
Company & Industry Overviews.How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
Company & Industry Overviews.Understanding Sarepta Therapeutics’ Operational Performance
Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.
Company & Industry Overviews.Vertex Pharmaceuticals’ Gross Margin Trends
Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.
Company & Industry Overviews.Do Analysts See Any Upside for Vertex Stock?
Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”
Company & Industry Overviews.Taking Stock of Vertex’s Performance
Vertex Pharmaceuticals (VRTX) focuses on developing cystic fibrosis therapies and bringing them to market.
Company & Industry Overviews.Do Analysts See Any Upside for bluebird bio Stock?
In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.
Company & Industry Overviews.Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.
Company & Industry Overviews.Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
Company & Industry Overviews.How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Earnings Report.Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth
Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
Company & Industry Overviews.How Is Vertex Pharmaceuticals Positioned in October?
Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.
Company & Industry Overviews.Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
Company & Industry Overviews.Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
Company & Industry Overviews.How Vertex Pharmaceuticals Is Positioned Financially
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million.
Company & Industry Overviews.Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.
Company & Industry Overviews.Estimates and Recommendations for Bluebird Bio on September 6
Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.
Company & Industry Overviews.Bluebird Bio’s Valuation on September 6
Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.
Company & Industry Overviews.How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
Company & Industry Overviews.How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
Company & Industry Overviews An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept
Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.
Company & Industry Overviews.A Look at Incyte’s Valuation on August 22
On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.
Company & Industry Overviews.Why Vertex Is Expected to Report Robust EPS Growth in 2018
Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.
Company & Industry Overviews.Analyst Recommendations for Exelixis in August
In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.
Earnings Report.Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
Earnings Report.How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Earnings Report.Why Most Analysts Are Bullish on Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) is expected to incur selling, general, and administrative expenses of $117.10 million in Q2 2018 as compared with $92.91 million in Q2 2017.
Earnings Report.Will Vertex Pharmaceuticals Meet Analysts’ Q2 Expectations?
Analysts expect Vertex Pharmaceuticals’ revenues to increase by 31.65% from $516.91 million in Q2 2017 to $680.53 million in Q2 2018.
Earnings Report.How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release
Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.
Company & Industry Overviews.What’s behind Gemphire Therapeutics’ Stock Price Rise
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.
Company & Industry Overviews.Incyte’s Valuations on July 6
Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.
Company & Industry Overviews.How Ionis Pharmaceuticals’ Valuation Compares
Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.
Company & Industry Overviews.Could Symdeko Be Vertex Pharmaceuticals’ Long-Term Growth Driver?
In June, Health Canada approved Vertex Pharmaceuticals’ Symdeko for the treatment of the underlying cause of cystic fibrosis in individuals over 12 years old.
Company & Industry Overviews.Solid Biosciences’ Stock Price Rose 46.6% on June 19
On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.
Company & Industry Overviews.CRISPR, Intellia, and Caribou Receive a US Genome-Editing Patent
On June 19, the co-owners of intellectual property associated with CRISPR-Cas9 genome editing technology were granted a US patent.
Company & Industry Overviews.A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Company & Industry Overviews.What Led to MEI Pharma Stock’s 55% Rise Last Week?
MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.
Company & Industry Overviews.CRISPR Stock Has Seen Soild Growth in the Last 12 Months
CRISPR Therapeutics has risen 24% between May 11 and May 17.
Earnings Report.How Did Jazz Pharmaceuticals Perform in 1Q18?
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17.
Earnings Report.How Did Exelixis Perform in 1Q18?
In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.
Earnings Report.How Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.
Company & Industry Overviews.Analysts’ Recommendations for BioMarin Pharmaceutical
In March 2018, the EMA (European Medicines Agency) accepted BioMarin Pharmaceutical’s (BMRN) marketing authorization application for pegvaliase.
Company & Industry Overviews.Why Regeneron Pharmaceuticals’ Stock Price Fell
Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”
Company & Industry Overviews.Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
Company & Industry Overviews.Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
Company & Industry Overviews.How Did Kalydeco Perform in 4Q17 and 2017?
In 4Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco generated revenues of $256 million, a ~45% increase on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter (or QoQ) basis.
Company & Industry Overviews.Gilead Sciences on the Street in January: Analyst Recommendations
In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.
Company & Industry Overviews.Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients
Vertex Pharmaceuticals (VRTX) is currently involved in evaluating four triple combination regimens comprised of tezacaftor, ivacaftor, and one of the next-generation correctors.
Company & Industry Overviews.Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline
On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.
Company & Industry Overviews.Analyst Recommendations for Vertex Pharmaceuticals in January
Of the 27 analysts covering Vertex Pharmaceuticals in January 2018, ten have recommended a “strong buy,” while 13 have recommended a “buy.”
Company & Industry Overviews.Analysts’ Recommendations for Bioverativ in January 2018
Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.
Company & Industry Overviews.A Look at Ionis’s 3Q17 Revenue Stream
Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.
Company & Industry Overviews.How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Company & Industry Overviews.Analysts’ Recommendations for Eli Lilly in December 2017
Eli Lilly (LLY) stock has risen 16.1% over the last 12 months and 15.7% in 2017 year-to-date. Analysts are estimating the stock could fall 8.3% over the next 12 months.
Company & Industry Overviews.Analyst Recommendations for Alexion in December 2017
Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.”
Company & Industry Overviews.Analysts’ Recommendations for Regeneron
Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]
Earnings Report.Analyst Recommendations for Vertex Pharmaceuticals in October
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.
Company & Industry Overviews.How Kalydeco Could Be Vertex’s Steady Revenue Story
In 2016, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues of around $703 million, which represents ~11% growth on a YoY (year-over-year) basis.
Company & Industry Overviews.Gauging Alexion’s 2018 Growth with Soliris
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Soliris generated revenues of ~$814 million, which represented a ~16% YoY rise and a ~4% QoQ rise.
Company & Industry Overviews.Analysts’ Recommendations for Mylan in September 2017
In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.
Company & Industry Overviews.Analysts’ Recommendations for Regeneron in September 2017
Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”
Company & Industry Overviews.How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
Company & Industry Overviews.Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
Company & Industry Overviews.How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Company & Industry Overviews.Vertex Presented Successful Results for Cystic Fibrosis Treatment
Vertex Pharmaceuticals’ peers that are actively conducting research and development for CF drugs include Pfizer (PFE), PTC Therapeutics (PTCT), Proteostasis Therapeutics (PTI), Novartis, and Roche.
Company & Industry Overviews.Vertex Saw Successful Results from VX-440 Phase 2 Study
The positive data from the clinical trials will likely help Vertex Pharmaceuticals commercialize the drug.
Company & Industry Overviews.How Pfizer’s Rare Disease Franchise Stands after 2Q17
In 1H17, BeneFix generated revenues of ~$302 million, which reflected an ~18% decline on a YoY basis.
Company & Industry Overviews.Analyst Recommendations for Regeneron Pharmaceuticals in August
Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”
Company & Industry Overviews.New Patients and Alexion Pharmaceuticals’ Metabolic Franchise
Alexion Pharmaceuticals (ALXN) has reiterated its 2017 revenue guidance of $375.0 million–$400.0 million for its metabolic franchise.
Company & Industry Overviews.Alexion Pharmaceuticals Expects Robust Revenue for Soliris
Alexion Pharmaceuticals (ALXN) raised its 2017 revenue projections for Soliris from $3.025 billion–$3.1 billion to $3.075 billion–$3.125 billion.
Company & Industry Overviews.Alexion Pharmaceuticals Raised 2017 Earnings Guidance
Alexion Pharmaceuticals (ALXN) raised its 2017 non-GAAP guidance from the previously estimated $5.10–$5.30 to $5.40–$5.55.
Company & Industry Overviews.Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Company & Industry Overviews.Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Company & Industry Overviews.Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Company & Industry Overviews.Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Company & Industry Overviews.Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens
On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.
Company & Industry Overviews.Vertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017
In 1Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues close to $186 million, of which $102 million came from the US market.
Company & Industry Overviews.Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
Miscellaneous.What Drove Biogen Stock in 2Q17?
Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.
Company & Industry Overviews.What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
Company & Industry Overviews.Inside Vertex Pharmaceuticals’ Clinical Pipeline
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Company & Industry Overviews.Inside Vertex Pharmaceuticals’ Revenue Trend
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
Company & Industry Overviews.What Analysts Recommend for Celgene in 2017
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
Company & Industry Overviews.How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
Company & Industry Overviews.ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
Company & Industry Overviews.Alexion Pharmaceuticals Projects Robust 2017 Revenue Performance
Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.
Earnings Report.Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17
To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.
Earnings Report.Biogen Has Developed a Robust Access Strategy for Spinraza
In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market.
Earnings Report.Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17
Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016.
Earnings Report.Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17?
In 2017, Regeneron expects its eye drug, Eylea, to witness single-digit revenue growth on a year-over-year basis. Eylea has continued to be the company’s major revenue driver in the year.
Miscellaneous.Failed Healthcare Bill Will Impact the Pharmaceutical Industry
Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.
Company & Industry Overviews.Ionis’s Subsidiary Akcea Therapeutics and Volanesorsen
Ionis Pharmaceuticals (IONS) formed Akcea Therapeutics, a wholly owned subsidiary, to develop and commercialize volanesorsen.
Company & Industry Overviews.A Look at Ionis Pharmaceuticals’ Spinraza
Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease.
Company & Industry Overviews.Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.